Table 4 Clinical parameters of individuals in the study with different genotypes with respect to AGO1 and AGO2 polymorphisms.

From: Association study of AGO1 and AGO2 genes polymorphisms with recurrent pregnancy loss

Control

Patients

Genotypes

Hct (%)

PLT(103/ul)

BMI (kg/m2)

Hcy (μmol/L)

Genotypes

Hct (%)

PLT (103/ul)

BMI (kg/m2)

Hcy (μmol/L)

TG (mg/dl)

FBS (mg/dl)

Mean ± SD

Mean ± SD

Mean ± SD

Mean ± SD

Mean ± SD

Mean ± SD

Mean ± SD

Mean ± SD

Mean ± SD

Mean ± SD

AGO1 rs595961G>A

AGO1 rs595961G>A

   GG

35.62 ± 4.21

233.03 ± 64.52

21.47 ± 2.96

8.38 ± 1.31

GG

37.40 ± 3.12

252.52 ± 51.74

21.33 ± 3.30

6.94 ± 2.00

191.00 ± 167.11

94.30 ± 14.12

   GA

35.71 ± 4.57

250.77 ± 69.72

22.14 ± 4.44

7.18 ± 1.55

GA

37.41 ± 3.67

266.31 ± 76.47

22.25 ± 5.23

7.11 ± 2.36

168.20 ± 145.56

94.63 ± 16.80

   AA

38.83 ± 1.72

210.67 ± 65.42

—

—

AA

35.09 ± 5.04

237.63 ± 55.74

19.60 ± 2.00

6.94 ± 2.13

132.50 ± 55.60

119.00 ± 43.32

   Pa

0.436

0.238

0.379

0.281

P a

0.164

0.491b

0.028

0.842

0.706

0.089b

AGO1 rs636832A>G

AGO1 rs636832A>G

   AA

35.09 ± 4.42

233.36 ± 69.62

21.81 ± 3.47

8.10 ± 1.79

AA

37.28 ± 3.13

252.97 ± 53.04

21.21 ± 2.93

6.96 ± 1.97

196.44 ± 179.46

94.91 ± 15.03

   AG

36.79 ± 3.71

241.24 ± 61.27

21.38 ± 3.12

7.23 ± 0.68

AG

37.71 ± 3.52

250.89 ± 61.04

22.08 ± 5.15

6.83 ± 2.14

147.07 ± 103.47

93.15 ± 14.72

   GG

34.63 ± 5.20

243.38 ± 52.04

19.35 ± 1.25

—

GG

35.69 ± 4.00

294.06 ± 80.67

20.75 ± 2.53

7.96 ± 2.61

224.33 ± 187.00

107.06 ± 31.04

   Pa

0.026b

0.704

0.417

0.655b

P a

0.093

0.023

0.084

0.079

0.670b

0.044b

AGO2 rs2292779C>G

AGO2 rs2292779C>G

   CC

35.68 ± 4.64

232.55 ± 62.67

21.48 ± 3.03

7.36 ± 1.27

CC

37.19 ± 3.74

254.61 ± 64.40

21.13 ± 2.97

7.00 ± 2.04

209.00 ± 174.22

96.07 ± 18.74

   CG

36.24 ± 3.79

244.22 ± 64.62

21.86 ± 3.92

8.47 ± 1.79

CG

37.27 ± 3.20

248.93 ± 50.39

21.94 ± 4.39

7.04 ± 2.28

152.59 ± 135.21

93.96 ± 16.32

   GG

33.29 ± 4.49

215.53 ± 77.13

21.39 ± 2.55

—

GG

37.75 ± 2.73

275.34 ± 64.30

20.97 ± 4.15

6.75 ± 1.60

203.33 ± 172.12

96.70 ± 13.51

   Pa

0.011

0.138

0.819

0.342

P a

0.726

0.096

0.117

0.769

0.339

0.629

AGO2 rs4961280C>A

AGO2 rs4961280C>A

   CC

35.75 ± 4.39

235.79 ± 66.96

21.57 ± 3.09

7.98 ± 1.44

CC

37.19 ± 3.38

255.96 ± 59.07

21.53 ± 3.86

7.13 ± 2.14

169.60 ± 149.42

95.76 ± 17.67

   CA

35.23 ± 3.28

243.27 ± 57.69

22.01 ± 4.82

7.43 ± 1.79

CA

37.70 ± 3.27

250.82 ± 61.82

20.97 ± 3.68

6.17 ± 1.70

207.55 ± 151.97

93.11 ± 13.76

   AA

—

—

—

—

AA

40.95 ± 1.48

289.50 ± 2.12

24.26 ± 5.01

6.18 ± 0.74

603.00 ± 0.00

90.00 ± 7.07

   Pa

0.591

0.618

0.636

0.649

P a

0.222

0.646

0.162

0.027

0.017

0.635

  1. ANOVA, analysis of variance; SD, standard deviation; Hct, Hematocrit; PLT, platelet; Hcy, Homocysteine; BMI, body mass index; TG, Triglyceride; FBS, fasting blood sugar. aCalculated using ANOVA. bWe were calculated using the Kruskal-Wallis test for continuous data when F-test P-value for equal variances was lower than 0.05.
Back to article page